tbuckley/cabot-search huggingface dataset:
Combined Whole Eye and Face Transplant
Authors: Daniel J. Ceradini, David L. Tran, Vaidehi S. Dedania, Bruce E. Gelb, Oriana D. Cohen, Roberto L. Flores, Jamie P. Levine, Pierre B. Saadeh, David A. Staffenberg, Zakia Ben Youss, Patryk Filipiak, Steven H. Baete, Eduardo D. Rodriguez
Journal: JAMA (2024)

Importance Catastrophic facial injury with globe loss remains a formidable clinical problem with no previous reports of reconstruction by whole eye or combined whole eye and facial transplant. Objective To develop a microsurgical strategy for combined whole eye and facial transplant and describe the clinical findings during the first year following transplant. Design, Setting, and Participant A 46-year-old man who sustained a high-voltage electrical injury with catastrophic tissue loss to his face and left globe underwent combined whole eye and face transplant using personalized surgical devices and a novel microsurgical strategy at a specialized center for vascularized composite allotransplantation. Main Outcomes and Measures Reperfusion and viability of the whole eye and facial allografts, retinal function, and incidence of acute rejection. Results The patient underwent a combined whole eye and face transplant from an immunologically compatible donor with primary optic nerve coaptation and conventional postoperative immunosuppression. Globe and retinal perfusion were maintained throughout the immediate postoperative period, evidenced by fluorescein angiography. Optical coherence tomography demonstrated atrophy of inner retinal layers and attenuation and disruption of the ellipsoid zone. Serial electroretinography confirmed retinal responses to light in the transplanted eye. Using structural and functional magnetic resonance imaging, the integrity of the transplanted visual pathways and potential occipital cortical response to light stimulation of the transplanted eye was demonstrated. At 1 year post transplant (postoperative day 366), there was no perception of light in the transplanted eye. Conclusions and Relevance This is the first report of whole eye transplant combined with facial transplant, demonstrating allograft survival including rejection-free graft survival and electroretinographic measurements indicating retinal response to light stimuli. These data highlight the potential for clinical allotransplantation for globe loss.
Nurse-Supported Self-Directed Cognitive Behavioral Therapy for Insomnia
Authors: Christi S. Ulmer, Corrine I. Voils, Amy S. Jeffreys, Maren Olsen, Jennifer Zervakis, Kaitlyn Goodwin, Pamela Gentry, Cynthia Rose, Hollis J. Weidenbacher, Jean C. Beckham, Hayden B. Bosworth
Journal: JAMA Internal Medicine (2024)

Importance Cognitive behavioral therapy for insomnia (CBTi) is the standard of care for treating insomnia disorder, but access is limited. Alternative approaches are needed to expand access to the standard of care. Objective To examine the effectiveness of a nurse-supported, self-directed behavioral insomnia intervention for decreasing insomnia severity and improving sleep outcomes among veterans, a population with considerable mental health comorbidity. Design, Setting, and Participants This randomized clinical trial included 178 patients with insomnia disorder who were recruited from a Veterans Affairs hospital (Durham VA Healthcare System) from September 2019 to April 2022 and randomized following baseline assessment; follow-ups were conducted at 8 weeks (primary end point) and 6 months. Data analysis was primarily conducted during the summer of 2023 and concluded in May 2024. Intervention Six weekly phone calls from a nurse interventionist plus assigned treatment manual readings covering CBTi treatment components. The health education manual focused on health topics but not sleep. Main Outcomes and Measures The primary outcome was the Insomnia Severity Index (score range, 0-28; remission &amp;amp;lt;8; differential improvement of 3 points targeted) score assessed at 8 weeks postrandomization. Secondary outcomes were sleep outcomes, depression, fatigue, treatment response, and remission. Results Of 178 study participants, the mean (SD) age was 55.1 (13.2) years, and 128 (71.9%) identified as men. At 8 weeks, Insomnia Severity Index scores decreased by an estimated mean (SE) of 5.7 (0.51) points in the intervention group and 2.0 (0.47) points in the control group, a differential mean improvement of 3.7 points (95% CI, −5.0 to −2.4; P &amp;amp;lt; .001). Differences were sustained at 6 months (mean, −2.8; 95% CI, −4.4 to −1.3; P &amp;amp;lt; .001). The intervention also resulted in greater improvements at 8 weeks postrandomization in diary sleep onset latency, wake after sleep onset, and sleep efficiency and actigraphy sleep efficiency; these differences were sustained at 6 months. At 8 weeks, depression and fatigue were significantly reduced, and the odds of treatment response and remission were greater in the intervention group compared with controls. Conclusions and Relevance This randomized clinical trial found that despite greater prevalence of mental health conditions and sleep difficulties among veterans, a nurse-supported self-directed CBTi was more effective than health education control for reducing insomnia severity and improving sleep outcomes. Although less effective than therapist-delivered CBTi, findings were comparable with other trials using modified CBTi protocols. Trial Registration ClinicalTrials.gov Identifier: NCT03727438
Error Management Training and Adaptive Expertise in Learning Computed Tomography Interpretation
Authors: Leonardo Aliaga, Rebecca A. Bavolek, Benjamin Cooper, Amy Mariorenzi, James Ahn, Aaron Kraut, David Duong, Catherine Burger, Michael A. Gisondi
Journal: JAMA Network Open (2024)

Importance Adaptive expertise helps physicians apply their skills to novel clinical cases and reduce preventable errors. Error management training (EMT) has been shown to improve adaptive expertise with procedural skills; however, its application to cognitive skills in medical education is unclear. Objective To evaluate whether EMT improves adaptive expertise when learning the cognitive skill of head computed tomography (CT) interpretation. Design, Setting, and Participants This 3-arm randomized clinical trial was conducted from July 8, 2022, to March 30, 2023, in 7 geographically diverse emergency medicine residency programs. Participants were postgraduate year 1 through 4 emergency medicine residents masked to the hypothesis. Interventions Participants were randomized 1:1:1 to a difficult EMT, easy EMT, or error avoidance training (EAT) control learning strategy for completing an online head CT curriculum. Both EMT cohorts received no didactic instruction before scrolling through head CT cases, whereas the EAT group did. The difficult EMT cohort answered difficult questions about the teaching cases, leading to errors, whereas the easy EMT cohort answered easy questions, leading to fewer errors. All 3 cohorts used the same cases. Main Outcomes and Measures The primary outcome was a difference in adaptive expertise among the 3 cohorts, as measured using a head CT posttest. Secondary outcomes were (1) differences in routine expertise, (2) whether the quantity of errors during training mediated differences in adaptive expertise, and (3) the interaction between prior residency training and the learning strategies. Results Among 212 randomized participants (mean [SD] age, 28.8 [2.0] years; 107 men [50.5%]), 70 were allocated to the difficult EMT, 71 to the easy EMT, and 71 to the EAT control cohorts; 150 participants (70.8%) completed the posttest. The difficult EMT cohort outperformed both the easy EMT and EAT cohorts on adaptive expertise cases (60.6% [95% CI, 56.1%-65.1%] vs 45.2% [95% CI, 39.9%-50.6%], vs 40.9% [95% CI, 36.0%-45.7%], respectively; P &amp;amp;lt; .001), with a large effect size (η 2 = 0.19). There was no significant difference in routine expertise. The difficult EMT cohort made more errors during training than the easy EMT cohort. Mediation analysis showed that the number of errors during training explained 87.2% of the difficult EMT learning strategy’s effect on improving adaptive expertise ( P = .01). The difficult EMT learning strategy was more effective in improving adaptive expertise for residents earlier in training, with a large effect size (η 2 = 0.25; P = .002). Conclusions and Relevance In this randomized clinical trial, the findings show that EMT is an effective method to develop physicians’ adaptive expertise with cognitive skills. Trial Registration ClinicalTrials.gov Identifier: NCT05284838
Scabies, Bedbug, and Body Lice Infestations
Authors: Cristina Thomas, Herbert Castillo Valladares, Timothy G. Berger, Aileen Y. Chang
Journal: JAMA (2024)

Importance Scabies, bedbug, and body lice infestations are caused by organisms that live on or in the skin, on clothing, or in the environment and commonly cause pruritus and rash. In 2021, approximately 622 million incident cases of scabies occurred globally. Data on bedbug infestations are limited. Body lice prevalence ranges from 4.1% to 35% among persons experiencing homelessness worldwide. Observations Scabies is caused by mites ( Sarcoptes scabiei ) that burrow into the epidermis. Transmission primarily occurs from prolonged skin-to-skin contact with an individual who has an infestation. Common scabies is characterized by excoriated pruritic papules, plaques, and pathognomonic burrows on finger/toe web spaces, volar wrists, ankles, axillae, buttocks, male genitalia, and areolae. Permethrin cream and oral ivermectin are first-line treatments for adults, with similar clearance rates by week 2 (74% with permethrin vs 68% with ivermectin; relative risk, 0.91; 95% CI, 0.76-1.08). Treatment failure can occur with oral ivermectin (11.8%; 95% CI, 8.4%-15.4%) and topical permethrin (10.8%; 95% CI, 7.5%-14.5%). Bedbugs ( Cimex lectularius , Cimex hemipterus ) are insects that live on mattresses and furniture and feed on blood nocturnally, causing linear pruritic erythematous papules. New skin lesions on waking, cohabitants with similar symptoms, and recently residing in a high-occupancy setting should raise suspicion. Treatment requires eradication with pest management. Body lice ( Pediculus humanus humanus ) are insects found on clothing that travel to the skin for blood meals. Body lice bites cause pruritic excoriated macules/papules and hyperpigmentation in areas where clothing seams contact skin. Treatment and prevention require at least once-weekly bathing and laundering of clothing and bedding. Conclusions and Relevance Scabies, bedbug, and body lice infestations are common. Accurate diagnosis requires taking a history, including social drivers of health (eg, housing status, living environment), and physical examination. First-line treatments include scabicides for patients with common scabies and their close contacts. Scabies, bedbug, and body lice infestations should be treated with decontamination measures.
Lactated Ringer vs Normal Saline Solution During Sickle Cell Vaso-Occlusive Episodes
Authors: Augusta K. Alwang, Anica C. Law, Elizabeth S. Klings, Robyn T. Cohen, Nicholas A. Bosch
Journal: JAMA Internal Medicine (2024)

Importance Sickle cell disease (SCD), a clinically heterogenous genetic hemoglobinopathy, is characterized by painful vaso-occlusive episodes (VOEs) that can require hospitalization. Patients admitted with VOEs are often initially resuscitated with normal saline (NS) to improve concurrent hypovolemia, despite preclinical evidence that NS may promote erythrocyte sickling. The comparative effectiveness of alternative volume-expanding fluids (eg, lactated Ringer [LR]) for resuscitation during VOEs is unclear. Objective To compare the effectiveness of LR to NS fluid resuscitation in patients with SCD and VOEs. Design, Setting, and Participants This multicenter cohort study and target trial emulation included inpatient adults with SCD VOEs who received either LR or NS on hospital day 1. The Premier PINC AI database (2016-2022), a multicenter clinical database including approximately 25% of US hospitalizations was used. The analysis took place between October 6, 2023, and June 20, 2024. Exposure Receipt of LR (intervention) or NS (control) on hospital day 1. Main Outcome and Measures The primary outcome was hospital-free days (HFDs) by day 30. Targeted maximum likelihood estimation was used to calculate marginal effect estimates. Heterogeneity of treatment effect was explored in subgroups. Results A total of 55 574 patient encounters where LR (n = 3495) or NS (n = 52 079) was administered on hospital day 1 were included; the median (IQR) age was 30 (25-37) years. Patients who received LR had more HFDs compared with those who received NS (marginal mean difference, 0.4; 95% CI, 0.1-0.6 days). Patients who received LR also had shorter hospital lengths of stay (marginal mean difference, −0.4; 95% CI, −0.7 to −0.1 days) and lower risk of 30-day readmission (marginal risk difference, −5.8%; 95% CI, −9.8% to −1.8%). Differences in HFDs between LR and NS were heterogenous based on fluid volume received: among patients who received less than 2 L, there was no difference in LR vs NS; among those who received 2 or more L, LR was superior to NS. Conclusion and Relevance This cohort study found that, compared with NS, LR had a small but significant improvement in HFDs and secondary outcomes including 30-day readmission. These results suggest that, among patients with VOEs in whom clinicians plan to give volume resuscitation fluids on hospital admission, LR should be preferred over NS.
Ending Unequal Treatment and Achieving Optimal Health for All
Authors: Georges C. Benjamin, Jennifer E. DeVoe, Francis K. Amankwah
Journal: JAMA (2024)

This Viewpoint discusses the findings of a recent National Academies of Sciences, Engineering, and Medicine report suggesting that current health care delivery and accountability structures perpetuate, rather than reduce, health inequities and details several changes needed to address these structural problems.
Phenotypic and spatial heterogeneity of CD8+ tumour infiltrating lymphocytes
Authors: Yikan Sun, Eloy Yinwang, Shengdong Wang, Zenan Wang, Fangqian Wang, Yucheng Xue, Wenkan Zhang, Shenzhi Zhao, Haochen Mou, Shixin Chen, Lingxiao Jin, Binghao Li, Zhaoming Ye
Journal: Molecular Cancer (2024)
Fibrotic response to anti-CSF-1R therapy potentiates glioblastoma recurrence
Authors: Spencer S Watson, Anoek Zomer, Nadine Fournier, Joao Lourenco, Manfredo Quadroni, Agnieszka Chryplewicz, Sina Nassiri, Pauline Aubel, Simona Avanthay, Davide Croci, Erik Abels, Marike L D Broekman, Douglas Hanahan, Jason T Huse, Roy T Daniel, Monika E Hegi, Krisztian Homicsko, Giulia Cossu, Andreas F Hottinger, Johanna A Joyce
Journal: Cancer Cell (2024)
Circulating tumor DNA-based stratification strategy for chemotherapy plus PD-1 inhibitor in advanced non-small-cell lung cancer
Authors: Jiachen Xu, Rui Wan, Yiran Cai, Shangli Cai, Lin Wu, Baolan Li, Jianchun Duan, Ying Cheng, Xiaoling Li, Xicheng Wang, Liang Han, Xiaohong Wu, Yun Fan, Yan Yu, Dongqing Lv, Jianhua Shi, Jianjin Huang, Shaozhang Zhou, Baohui Han, Guogui Sun, Qisen Guo, Youxin Ji, Xiaoli Zhu, Sheng Hu, Wei Zhang, Qiming Wang, Yuming Jia, Ziping Wang, Yong Song, Jingxun Wu, Meiqi Shi, Xingya Li, Zhigang Han, Yunpeng Liu, Zhuang Yu, An-Wen Liu, Xiuwen Wang, Caicun Zhou, Diansheng Zhong, Liyun Miao, Zhihong Zhang, Hui Zhao, Jun Yang, Dong Wang, Yingyi Wang, Qiang Li, Xiaodong Zhang, Mei Ji, Zhenzhou Yang, Jiuwei Cui, Beili Gao, Buhai Wang, Hu Liu, Lei Nie, Mei He, Shi Jin, Wei Gu, Yongqian Shu, Tong Zhou, Jian Feng, Xinmei Yang, Cheng Huang, Bo Zhu, Yu Yao, Jianjun Yu, Sheng Yao, Runxi Shen, Zhijie Wang, Jie Wang
Journal: Cancer Cell (2024)
Glioblastoma induces the recruitment and differentiation of dendritic-like “hybrid” neutrophils from skull bone marrow
Authors: Meeki Lad, Angad S Beniwal, Saket Jain, Poojan Shukla, Venina Kalistratova, Jangham Jung, Sumedh S Shah, Garima Yagnik, Atul Saha, Ankita Sati, Husam Babikir, Alan T Nguyen, Sabraj Gill, Jennifer Rios, Jacob S Young, Austin Lui, Diana Salha, Aaron Diaz, Manish K Aghi
Journal: Cancer Cell (2024)
m6A mRNA methylation in brown fat regulates systemic insulin sensitivity via an inter-organ prostaglandin signaling axis independent of UCP1
Authors: Ling Xiao, Dario F De Jesus, Cheng-Wei Ju, Jiang Bo Wei, Jiang Hu, Ava DiStefano-Forti, Tadataka Tsuji, Cheryl Cero, Ville Männistö, Suvi M Manninen, Siying Wei, Oluwaseun Ijaduola, Matthias Blüher, Aaron M Cypess, Jussi Pihlajamäki, Yu-Hua Tseng, Chuan He, Rohit N Kulkarni
Journal: Cell Metabolism (2024)
FDA Approval Summary: Belzutifan for Patients with Advanced Renal Cell Carcinoma
Authors: Jaleh Fallah, Brian L. Heiss, Hee-Koung Joeng, Chana Weinstock, Xin Gao, William F. Pierce, Benjamin Chukwurah, Vishal Bhatnagar, Mallorie H. Fiero, Laleh Amiri-Kordestani, Richard Pazdur, Paul G. Kluetz, Daniel L. Suzman
Journal: Clinical Cancer Research (2024)

On December 14, 2023, the United States Food and Drug Administration (FDA) approved belzutifan (Welireg, Merck & Co., Inc.) for patients with advanced renal cell carcinoma (RCC) following a programmed death receptor-1 or programmed death-ligand 1 (PD-1/PD-L1) inhibitor and a vascular endothelial growth factor tyrosine kinase inhibitor (VEGF-TKI). FDA granted traditional approval based on LITESPARK-005 (NCT04195750), an open-label, randomized, head-to-head trial of 746 patients with advanced RCC that progressed following both a PD-1/PD-L1 inhibitor and a VEGF-TKI. Patients were randomized (1:1) to receive belzutifan or everolimus. The primary endpoints were progression-free survival (PFS) assessed by blinded independent central review (BICR) and overall survival (OS). A statistically significant improvement in PFS was demonstrated for belzutifan compared with everolimus [hazard ratio (HR)=0.75 (95% CI: 0.63, 0.90); 1-sided p-value=0.0008]. Kaplan-Meier curves reflected non-proportional hazards with similar median PFS estimates of 5.6 months (95% CI: 3.9, 7.0) in the belzutifan arm and 5.6 months (95% CI: 4.8, 5.8) in the everolimus arm. While not reaching full maturity, OS results appeared to show a favorable trend in the belzutifan arm compared to everolimus [HR=0.88 (95% CI: 0.73, 1.07)]. The confirmed objective response rate by BICR was 22% and 3.6% in belzutifan and everolimus arms, respectively. Observed toxicities differed between treatment arms, but drug discontinuations and interruptions due to treatment-emergent adverse events were lower on the belzutifan arm compared to the everolimus arm, and a descriptive analysis of patient-reported symptom and functional outcomes was suggestive of favorable tolerability for belzutifan compared to everolimus.
Early-life tobacco exposure is causally implicated in aberrant RAG-mediated recombination in childhood acute lymphoblastic leukemia
Authors: Tanxin Liu, Keren Xu, Anmol Pardeshi, Swe Swe Myint, Alice Y Kang, Libby M Morimoto, Michael R Lieber, Joseph L Wiemels, Scott C Kogan, Catherine Metayer, Adam J de Smith
Journal: Leukemia (2024)
PIONEER big data platform for prostate cancer: lessons for advancing future real-world evidence research
Authors: Ailbhe Lawlor, Katharina Beyer, Beth Russell, Carl Steinbeisser, Anders Bjartell, Bertrand De Meulder, Muhammad Imran Omar, Tim Hulsen, John Butler, James N'Dow, Juan Gómez Rivas, Giorgio Gandaglia, Rossella Nicoletti, Vasileios Sakalis, Emma Jane Smith, Monika Maass, Jihong Zong, Louise Fullwood, Thomas Abbott, Azadeh Tafreshiha, Kishore Papineni, Robert Snijder, Denis Horgan, Sarah Seager, Susan Evans-Axelsson, Maria J Ribal, Monique J Roobol, Mieke Van Hemelrijck
Journal: Nature Reviews Urology (2024)
Effects of Sotagliflozin on Health Status in Patients With Worsening Heart Failure
Authors: Ankeet S Bhatt, Deepak L Bhatt, Ph Gabriel Steg, Michael Szarek, Christopher P Cannon, Lawrence A Leiter, Darren K McGuire, Julia B Lewis, Matthew C Riddle, Adriaan A Voors, Marco Metra, Lars H Lund, Jeffrey M Testani, Christopher S Wilcox, Michael Davies, Bertram Pitt, Mikhail N Kosiborod
Journal: Journal of the American College of Cardiology (2024)
Zongertinib (BI 1810631), an irreversible HER2 TKI, spares EGFR signaling and improves therapeutic response in preclinical models and patients with HER2-driven cancers
Authors: Birgit Wilding, Lydia Woelflingseder, Anke Baum, Krzysztof Chylinski, Gintautas Vainorius, Neil Gibson, Irene C. Waizenegger, Daniel Gerlach, Martin Augsten, Fiona Spreitzer, Yukina Shirai, Masachika Ikegami, Sylvia Tilandyova, Dirk Scharn, Mark A. Pearson, Johannes Popow, Anna C. Obenauf, Noboru Yamamoto, Shunsuke Kondo, Frans L. Opdam, Annemarie Bruining, Shinji Kohsaka, Norbert Kraut, John V. Heymach, Flavio Solca, Ralph A. Neumuller
Journal: Cancer Discovery (2024)

Abstract Mutations in ERBB2 (encoding HER2) occur in 2% to 4% of non–small cell lung cancer (NSCLC) and confer poor prognosis. ERBB-targeting tyrosine kinase inhibitors, approved for treating other HER2-dependent cancers, are ineffective in HER2-mutant NSCLC due to dose-limiting toxicities or suboptimal potency. We report the discovery of zongertinib (BI 1810631), a covalent HER2 inhibitor. Zongertinib potently and selectively blocks HER2, while sparing EGFR, and inhibits the growth of cells dependent on HER2 oncogenic driver events, including HER2-dependent human cancer cells resistant to trastuzumab deruxtecan. Zongertinib displays potent antitumor activity in HER2-dependent human NSCLC xenograft models and enhances the activities of antibody–drug conjugates and KRASG12C inhibitors without causing obvious toxicities. The preclinical efficacy of zongertinib translates in objective responses in patients with HER2-dependent tumors, including cholangiocarcinoma (SDC4–NRG1 fusion) and breast cancer (V777L HER2 mutation), thus supporting the ongoing clinical development of zongertinib. Significance: HER2-mutant NSCLC poses a challenge in the clinic due to limited options for targeted therapies. Pan-ERBB blockers are limited by wild-type EGFR–mediated toxicity. Zongertinib is a highly potent and wild-type EGFR–sparing HER2 inhibitor that is active in HER2-driven tumors in the preclinical and clinical settings.
Prognostic Value of Plasma Immunoglobulin G N-Glycome Traits in Pulmonary Arterial Hypertension
Authors: Ze-Jian Zhang, Chao Liu, Jie-Ling Ma, Jing-Si Ma, Jia Wang, Ruo-Nan Li, Dan Lu, Yu-Ping Zhou, Tian-Yu Lian, Si-Jin Zhang, Jing-Hui Li, Lan Wang, Kai Sun, Chun-Yan Cheng, Wen-Hui Wu, Xin Jiang, Zhi-Cheng Jing
Journal: Journal of the American College of Cardiology (2024)
Effect of Evogliptin on the Progression of Aortic Valvular Calcification
Authors: Jae-Kwan Song, Sahmin Lee, Yong-Jin Kim, Hyung-Kwan Kim, Jong-Won Ha, Eui-Young Choi, Seung-Woo Park, Sung-Ji Park, Yong-Hyun Park, Jae-Hyeong Park, Dong Heon Yang, Kye Hun Kim, Dong Hyun Yang, Sangwon Han, Sun Young Chae, Ji Sung Lee, Jong-Min Song, Goo-Yeong Cho
Journal: Journal of the American College of Cardiology (2024)
Metroticket approach in a retrospective cohort study to predict overall survival after surgical resection for intermediate stage hepatocellular carcinoma
Authors: Marjorie T. Q. Hoang, Ye Xin Koh, Rehena Sultana, John C. Allen, Dimitrios Moris, Peng Chung Cheow, Alexander Y.F. Chung, Prema Raj Jeyaraj, Peter O. P. Mack, London Lucien P. J. Ooi, Ek Khoon Tan, Jin Yao Teo, Juinn Huar Kam, Fiona N.N. Moe, Jacelyn S.S. Chua, Ashley W.Y. Ng, Jade S.Q. Goh, Brian K. P. Goh, Sabino Zani, Pierce K. H. Chow
Journal: International Journal of Surgery (2024)
Cardiovascular and all-cause mortality outcomes of adrenalectomy versus medical treatment in primary aldosteronism: an umbrella review
Authors: Sandeep Samethadka Nayak, Ehsan Amini-Salehi, Farahnaz Joukar, Pubali Biswas, Sara Nobakht, Negin Letafatkar, Parham Porteghali, Erfan Mohammadi-Vajari, Fariborz Mansour-ghanaei, Mona Javid, Arian Mirdamadi, Daniyal Ameen, Behrang Motamed, Soheil Hassanipour, Mohammad-Hossein Keivanlou
Journal: International Journal of Surgery (2024)